Based on positive APEX data, the 5 mg and 10 mg dose levels have advanced into the Phase 3 PEAK and PINNACLE studies in MESI • KSI-101 in MESI patients consistently showed robust anatomic and visual responses in the Apex study conducted in the U.S. and in the clinical cohort from tertiary uveitis centers in Asia ‒ Over half of patients achieved at least a ≥15 letter gain ‒ Dryness was achieved after a single injection with sustained dryness observed during follow-up ‒ Consistent responses were observed irrespective of different underlying etiologies • PEAK and PINNACLE Phase 3 studies in MESI are actively enrolling 19 PEAK: NCT06990399. PINNACLE: NCT06996080 Key inclusion criteria • Macular edema secondary to inflammation • Diagnosis of active or inactive non-infectious intraocular inflammation, acute or chronic • Active leakage as evidenced by fluorescein angiogram • OCT CST of ≥320 microns • BCVA score ≤78 and ≥25 (~20/25 to 20/320 Snellen) Mean change in BCVA from Day 1 to the average of Week 20 and Week 24